EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ATG16L1 and OPTN as a novel prognostic gene expression signature in acute myeloid leukemia survival

Alexandra Teixeira, João M Alves, Nuria Estévez-Gómez, Ângela Fernandes, Nuno Cerveira, Susana Bizarro, Manuel R Teixeira, Manuel Guerreiro, Isabel Castro, Belém Sampaio-Marques, José Mariz, Sara Abalde-Cela und 3 weitere

Frontiers in Oncology · 05.05.2026 · 16

DOI: 10.3389/fonc.2026.1784384 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 05.05.2026. Verfasst von Alexandra Teixeira und 14 weiteren Autor:innen. Beteiligte Einrichtung: International Iberian Nanotechnology Laboratory (INL), Braga, Portugal. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) is the most frequent type of leukaemia in adults, often with poor outcomes due to the complex genetic landscape and low treatment efficacy. Autophagy, a conserved degradation process, plays an indispensable and context-dependent role in AML. This work explored the prognostic impact of autophagy-related genes compared to known AML-related genes. A two-gene signature (ATG16L1-OPTN) demonstrated that the expression of these autophagy-related genes correlates significantly with overall survival (OS). Cox regression analysis and validation in two larger cohorts (BEATAML2andTCGA LAML) confirmed the association of this signature with worst OS, reinforcing its clinical relevance. These results suggest the ATG16L1-OPTN signature as a novel and robust prognostic marker for predicting OS in AML patients.

Schlagwörter

Stichwörter der Autor:innen

ATG16L1OPTNacute myeloid leukemia (AML)autophagyoverall survival (OS)

Autor:innen und Institutionen

  • International Iberian Nanotechnology Laboratory (INL), Braga, Portugal.
  • Life and Health Sciences Research Institute (ICVS), Escola de Medicina, Universidade do Minho, Braga, Portugal.
  • ICVS/3B's - PT Government Associate Laboratory, Braga, Portugal.
  • Centro de Investigación en Nanomateriais e Biomedicina (CINBIO), Universidade de Vigo, Vigo, Spain.
  • Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain.
  • Department of Genetics, Portuguese Oncology Institute-Porto (IPO-Porto)/Porto Comprehensive Cancer Center, Porto, Portugal.

Zitieren

APA

Teixeira, A., Alves, J. M., Estévez-Gómez, N., Fernandes, Â., Cerveira, N., Bizarro, S., Teixeira, M. R., Guerreiro, M., Castro, I., Sampaio-Marques, B., Mariz, J., Abalde-Cela, S., Diéguez, L., Posada, D., & Ludovico, P. (2026). ATG16L1 and OPTN as a novel prognostic gene expression signature in acute myeloid leukemia survival. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1784384

Vancouver

Teixeira A, Alves JM, Estévez-Gómez N, Fernandes Â, Cerveira N, Bizarro S, et al. ATG16L1 and OPTN as a novel prognostic gene expression signature in acute myeloid leukemia survival. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1784384

BibTeX
@article{Teixeira2026,
  author = {Teixeira, Alexandra and Alves, João M and Estévez-Gómez, Nuria and Fernandes, Ângela and Cerveira, Nuno and Bizarro, Susana and Teixeira, Manuel R and Guerreiro, Manuel and Castro, Isabel and Sampaio-Marques, Belém and Mariz, José and Abalde-Cela, Sara and Diéguez, Lorena and Posada, David and Ludovico, Paula},
  title = {ATG16L1 and OPTN as a novel prognostic gene expression signature in acute myeloid leukemia survival},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1784384}
}
Kostenlos starten →